Literature DB >> 32389896

The impact of the European School of Oncology masterclass in clinical oncology on self-professional development.

Nicholas Pavlidis1, Fedro A Peccatori2, Matti Aapro3, Alex Eniu4, Stanley Kay5, Christian Rolfo6, Franco Cavalli7, Alberto Costa8.   

Abstract

We investigated the impact of the European School of Oncology's (ESO) Masterclass (MCO) in Clinical Oncology on the career development of young participants. MCO represents the flagship educational activity of ESO and is organized annually, mostly in collaboration with the European Society for Medical Oncology (ESMO) in five different geographical regions. A questionnaire consisting of 21 questions was sent to all doctors who attended the ESO MCOs from 2009 to 2016. The 228 responders were mostly from European countries and hold the specialty of Medical Oncology. Ninety-five percent of them evaluated ESO MCOs as "extremely useful" or "useful" for their professional career. Around 60% were trained at University Hospitals or Cancer Institutes and currently, one-third of them are employed in Academic Centers. Eighty percent have performed translational or clinical research and 77.5% were able to publish in pertinent international journals. The contribution of ESO MCOs to trainees' career development in different oncology disciplines around the world is discussed.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer education; Career development; ESO; European School of Oncology; Impact on professional development; Masterclass in clinical oncology

Mesh:

Year:  2020        PMID: 32389896     DOI: 10.1016/j.critrevonc.2020.102976

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  1 in total

1.  The Contribution of the European School Of Oncology Education to the Central Asian and Caucasian Regions.

Authors:  Nicholas Pavlidis; Alisher Kahharov; Fedro A Peccatori; Matti Aapro; Alex Eniu; Elie Rassy; Franco Cavalli; Alberto Costa
Journal:  J Cancer Educ       Date:  2021-07-22       Impact factor: 2.037

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.